ProCE Banner Activity

Driving Progress in HNSCC: Integrating Immunotherapy and Novel Targeted Therapies Across the Disease Continuum

Slideset

Download this slideset featuring expert perspectives on the use of immune checkpoint inhibitor therapy for recurrent/metastatic HNSCC, as well as a discussion of the evolving role of neoadjuvant/adjuvant immunotherapy for head and neck cancer.

Released: May 14, 2025

Expiration: November 13, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Coherus BioSciences, Inc. and Merck Sharp & Dohme Corp.

Coherus BioSciences, Inc.

Merck Sharp & Dohme Corp.